Related Experiment Video

Updated: Mar 17, 2026

A 3D Organotypic Melanoma Spheroid Skin Model
08:49

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

16.7K

PIM kinases as therapeutic targets against advanced melanoma

Batool Shannan1,2, Andrea Watters1, Quan Chen1

  • 1Program of Cellular and Molecular Oncogenesis, Melanoma Research Center, The Wistar Institute, Philadelphia, PA, USA.

Oncotarget
|July 25, 2016
PubMed

Insights

Organometallic inhibitors targeting PIM kinases show promise for treating metastatic melanoma. These PIM kinase inhibitors reduced melanoma cell growth and survival, offering potential new therapeutic options.

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Discovery

Background:

  • Metastatic melanoma treatment faces challenges due to unequal patient response and tumor resistance.
  • Identifying novel therapeutic targets is crucial for improving melanoma treatment outcomes.

Purpose of the Study:

  • To screen organometallic inhibitors for novel melanoma targets.
  • To investigate the role of PIM kinases in melanoma proliferation and survival.

Main Methods:

  • Screening of organometallic inhibitors against normal and melanoma cells.
  • Assessment of PIM kinase expression in patient tumor tissues.
  • Knockdown studies to evaluate PIM1, PIM2, and PIM3 roles.
  • Inhibition of PIM isoforms using SGI-1776 in preclinical melanoma models.
  • Combination studies with BRAF and PI3K inhibitors.

Main Results:

  • A PIM kinase inhibitor preferentially inhibited melanoma cell proliferation, invasion, and viability.
  • PIM kinases are expressed in melanoma tumors before and after treatment.
  • PIM1 knockdown reduced melanoma cell proliferation and in vivo tumor growth.
  • Inhibition of all PIM isoforms with SGI-1776 reduced melanoma proliferation and survival.
  • Combination therapy with BRAF or PI3K inhibitors potentiated PIM inhibition effects.

Conclusions:

  • PIM kinases are promising therapeutic targets for metastatic melanoma.
  • PIM inhibitors, such as SGI-1776, demonstrate potential as additions to current melanoma targeted therapies.
  • Combination strategies involving PIM inhibitors may enhance treatment efficacy.
Keywords:
PIM kinasesSGI-1776melanomaorganometallicstherapy

More Related Videos

The Three-Dimensional Human Skin Reconstruct Model: a Tool to Study Normal Skin and Melanoma Progression11:02

The Three-Dimensional Human Skin Reconstruct Model: a Tool to Study Normal Skin and Melanoma Progression

Published on: August 3, 2011

51.1K
Author Spotlight: Assessing the Potential of Circulating Tumor Cells in Leptomeningeal Disease Research06:25

Author Spotlight: Assessing the Potential of Circulating Tumor Cells in Leptomeningeal Disease Research

Published on: March 29, 2024

1.7K

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.0K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
13.7K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.7K